Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more about PERSIST-1 here.
PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape
Recent Articles
Umbralisib Confers Durable Response, Tumor Reductions in Patients With Relapsed/Refractory Marginal Zone Lymphoma
While rituximab-based treatment has improved outcomes for patients with marginal zone lymphoma (MZL), most patients eventually have a disease relapse. According to results from...
Transgene Levels Not Sufficient for Treatment Decisions in CAR T-Cell–Treated Patients
An analysis of three clinical trials of tisagenlecleucel found that levels of chimeric antigen receptor (CAR) transgene (or the gene that is artificially introduced...
Gilteritinib Superior to Standard Chemotherapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
Treatment with the oral FLT3/AXL inhibitor gilteritinib led to longer overall survival (OS) in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), compared with...
Is There a Role for AHCT Consolidation in MCL in the Rituximab Era?
The availability of rituximab-containing induction regimens for patients with mantle cell lymphoma (MCL) has improved outcomes, but younger, transplant-eligible patients may benefit from consolidative...
No Benefit in Adding Rituximab to MBVP in CNS Lymphoma
Results from a phase III trial suggest there is no survival benefit of adding the anti-CD20 monoclonal antibody rituximab to a standard methotrexate-based chemo-therapy...
Current Issue
May 2019, Volume 5, Issue 6
This issue features a look at home-based care for hematologic disorders, strides in pediatric leukemia in El Salvador, and more.
